Vernal keratoconjunctivitis (VKC) is a chronic, severe allergy that affectsthe surfaces of the eyes. It most commonly occurs in boys living in warm, dry climates. Attacks associated with VKC are commo...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on vernal keratoconjunctivitis is limited partly due to its rarity and the lack of systematic clinical studies. As VKC primarily affects a small population, comprehensive research on its genetic basis and clinical features has not been extensively conducted. This can lead to feelings of isolation for those affected, but ongoing research may provide more insights over time.
To manage vernal keratoconjunctivitis effectively, consider consulting with an ophthalmologist who specializes in allergic eye conditions. They can provide tailored treatment options and monitor your symptoms. For additional support, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and potential connections to specialists. Participating in clinical trials may also be an option to consider, as they can provide access to new treatments and contribute to the understanding of VKC.
Currently, there are three FDA-approved treatments for VKC: Cromolyn sodium 4% ophthalmic solution, cyclosporine, and Lodoxamide tromethamine. Additionally, tacrolimus has been designated as an orphan drug and is in development. There are six active clinical trials investigating various aspects of VKC, which can be explored further at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=vernal%20keratoconjunctivitis. These ongoing studies may lead to new treatment options and a better understanding of the condition.
Actionable guidance for navigating care for vernal keratoconjunctivitis
To manage vernal keratoconjunctivitis effectively, consider consulting with an ophthalmologist who specializes in allergic eye conditions. They can provide tailored treatment options and monitor your symptoms. For additional support, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and potential connections to specialists. Participating in clinical trials may also be an option to consider, as they can provide access to new treatments and contribute to the understanding of VKC.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on vernal keratoconjunctivitis is limited partly due to its rarity and the lack of systematic clinical studies. As VKC primarily affects a small population, comprehensive research on its genetic basis and clinical features has not been extensively conducted. This can lead to feelings of isolation for those affected, but ongoing research may provide more insights over time.
To manage vernal keratoconjunctivitis effectively, consider consulting with an ophthalmologist who specializes in allergic eye conditions. They can provide tailored treatment options and monitor your symptoms. For additional support, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and potential connections to specialists. Participating in clinical trials may also be an option to consider, as they can provide access to new treatments and contribute to the understanding of VKC.
Currently, there are three FDA-approved treatments for VKC: Cromolyn sodium 4% ophthalmic solution, cyclosporine, and Lodoxamide tromethamine. Additionally, tacrolimus has been designated as an orphan drug and is in development. There are six active clinical trials investigating various aspects of VKC, which can be explored further at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=vernal%20keratoconjunctivitis. These ongoing studies may lead to new treatment options and a better understanding of the condition.
Actionable guidance for navigating care for vernal keratoconjunctivitis
To manage vernal keratoconjunctivitis effectively, consider consulting with an ophthalmologist who specializes in allergic eye conditions. They can provide tailored treatment options and monitor your symptoms. For additional support, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and potential connections to specialists. Participating in clinical trials may also be an option to consider, as they can provide access to new treatments and contribute to the understanding of VKC.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on vernal keratoconjunctivitis is limited partly due to its rarity and the lack of systematic clinical studies. As VKC primarily affects a small population, comprehensive research on its genetic basis and clinical features has not been extensively conducted. This can lead to feelings of isolation for those affected, but ongoing research may provide more insights over time.
To manage vernal keratoconjunctivitis effectively, consider consulting with an ophthalmologist who specializes in allergic eye conditions. They can provide tailored treatment options and monitor your symptoms. For additional support, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and potential connections to specialists. Participating in clinical trials may also be an option to consider, as they can provide access to new treatments and contribute to the understanding of VKC.
Currently, there are three FDA-approved treatments for VKC: Cromolyn sodium 4% ophthalmic solution, cyclosporine, and Lodoxamide tromethamine. Additionally, tacrolimus has been designated as an orphan drug and is in development. There are six active clinical trials investigating various aspects of VKC, which can be explored further at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=vernal%20keratoconjunctivitis. These ongoing studies may lead to new treatment options and a better understanding of the condition.
Actionable guidance for navigating care for vernal keratoconjunctivitis
To manage vernal keratoconjunctivitis effectively, consider consulting with an ophthalmologist who specializes in allergic eye conditions. They can provide tailored treatment options and monitor your symptoms. For additional support, you can explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org, which offers information and potential connections to specialists. Participating in clinical trials may also be an option to consider, as they can provide access to new treatments and contribute to the understanding of VKC.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
Organizations with orphan designations or approved therapies for this disease